Saturday, November 2, 2024
Home Tags Drug development

drug development Related News

New tetanus test identifies global immunity gaps

New tetanus test identifies global immunity gaps

Researchers from the University of Birmingham are developing a non-invasive saliva test that could identify children across the Global South missing immunity to tetanus...
DEFENCE’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...

Chiesi: Industry-leading respiratory health, rare diseases, and speciality care solutions

Chiesi is an international, research-oriented biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and speciality care. Chiesi invests continuously...

Defence Therapeutics’ AccuTOX® study published in the Journal of Translational Medicine

Defence Therapeutics has announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated AccuTOX®.
antibiotic drugs

Scientists pioneer new antimicrobial drugs from food by-products

Scientists are set to harness the potential of food by-products to manufacture antimicrobial drugs from bacteria.
AstraZeneca to invest £650m in UK's life sciences sector

AstraZeneca to invest £650m in UK’s life sciences sector

Pharmaceutical giant AstraZeneca has revealed plans to inject £650m into the UK, bolstering the nation's life sciences sector and propelling economic growth. This significant investment...
AccuTOX®

Defence Therapeutics granted US patent for AccuTOX® technology

Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
monoclonal antibody

Tohoku University develops monoclonal antibody for HER2-positive breast cancer

Tohoku University have engineered a groundbreaking monoclonal antibody aimed at HER2-positive breast cancer.
drug delivery

BioNxt acquires cutting-edge equipment to boost drug delivery product manufacturing

BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of...

Vektor Pharma: leaders in thin film drug formulations

Vektor Pharma TF GmbH and its team have been leaders in the design, testing, and manufacture of thin film drug formulations. Vektor Pharma TF GmbH ...
lung tumours

Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours

Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
vaccine technology

Defence Therapeutics awarded CIPO patent for vaccine technology

Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
DEFENCE’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

RECOVERY trial set to investigate revolutionary new flu treatments

The groundbreaking RECOVERY trial, celebrated for its discovery of four effective treatments for COVID-19, is broadening its horizons by venturing into the realm of...
cancer drug resistance

Researchers discover new target to combat cancer drug resistance

In a groundbreaking development, scientists at the University of Queensland have pinpointed a novel drug target with immense promise in combating cancer drug resistance...
Accum® technology

How Defence’s Accum® technology is advancing cancer therapeutics

Industry-leading biotechnology pioneer Defence Therapeutics details how the company is advancing immune oncology through its revolutionary Accum® technology. Whether using an antibody, cell-based vaccine or...
A boost for NervGen's spinal cord injury trials

A boost for NervGen’s spinal cord injury trials

Following the success of its phase I clinical trial, NervGen will initiate a phase Ib/IIa trial as early as Q3 this year to demonstrate...
biosimilars

How the potential of biosimilar medications can be unlocked

Health Europa details everything you need to know about biosimilar medications, their benefits, safety, success stories, and how biosimilars can revolutionise healthcare. The potential of...
mRNA cancer vaccine

Defence Therapeutics successfully develops ACCUMTM -mRNA cancer vaccine

Canadian biopharmaceutical pioneer Defence Therapeutics has revealed it has successfully conjugated mRNA molecules to AccumTM – a significant breakthrough that looks to enhance the...
biopharmaceuticals

Biopharmaceuticals – the complete guide to the future of medicine

Health Europa provides a comprehensive analysis of biopharmaceuticals to evaluate their significant potential to treat a range of diseases and their cost and value...
A new rapid treatment for IIH headaches is in development

A new rapid treatment for IIH headaches is in development

A new injectable peptide-based drug, normally used to treat type-2 diabetes, could treat IIH headaches.   A trial conducted by the University of Birmingham has found...

Pin It on Pinterest